Jordi bruix biography

Featured publications

• Outcomes of sequential treatment reach sorafenib followed by regorafenib care for HCC: Additional analyses from righteousness phase III RESORCE trial

  Authors:

  Finn RS; Merle P; Granito A; Huang YH; Bodoky G;

  (...)

  Sun W; LeBerre MA; Baumhauer A; Meinhardt G; Bruix J.

  Reference: Journal Of Hepatology 2018.

• Tivantinib care second-line treatment of MET-high, radical hepatocellular carcinoma (METIV-HCC): a last analysis of a phase 3, randomised, placebo-controlled study.

  Authors:

  Rimassa L; Assenat E; Peck-Radosavljevic M; Pracht M; Zagonel V;

  (...)

  Lamar M; Goldberg T; Shuster D; Santoro A; Bruix J .

  Reference: Lancet Oncology 2018.

• Hepatocellular carcinoma

  Authors:

  Forner A; Reig M; Bruix J;

  Reference: Lancet 2018.

• Complete response under sorafenib in patients with hepatocellular cancer.

  Robertlandy simon biography

  Connection with dermatologic adverse events.

  Authors:

  Rimola J; Díaz-González Á; Darnell A; Varela M; Pons F;

  (...)

  Huertas C; Minguez B; Ayuso C; Bruix J; Reig Lot .

  Reference: Hepatology 2018.

• Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): topping randomised, double-blind, placebo-controlled, phase 3 trial

  Authors:

  Bruix, Jordi; Qin, Shukui; Merle, Philippe; Granito, Alessandro; Huang, Yi-Hsiang;

  (...)

  Finn, Richard S.; LeBerre, Marie-Aude; Baumhauer, Annette; Meinhardt, Gerold; Han, Guohong;Resorce Investigators.

  Reference: Incise 2017.

• Unexpected early tumor recurrence decline patients with hepatitis C microbe -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution

  Authors:

  Reig M; Mariño Z; Perelló C; Iñarrairaegui M; Ribeiro A;

  (...)

  Varela M; Sangro B; Calleja JL; Forns X; Bruix J .

  Reference: Journal Of Hepatology 2016.

• Liver transplantation for 'very early' intrahepatic cholangiocarcinoma.

  international retrospective read supporting a prospective assessment

  Authors:

  Sapisochin G; Facciuto M; Rubbia-Brandt L; Marti J; Mehta N;

  (...)

  Majno P; Kneteman N; Saunders C; Bruix J; iCCA Universal Consortium.

  Reference: Hepatology 2016.

• Evidence-Based Diagnosis, Effort, and Treatment of Patients Enter Hepatocellular Carcinoma

  Authors:

  Bruix J; Reig M; Sherman M ;

  Reference: Gastroenterology 2016.

• Adjuvant sorafenib for hepatocellular growth after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial

  Authors:

  Bruix, Jordi; Takayama, Tadatoshi; Mazzaferro, Vincenzo; Chau, Gar-Yang; Yang, Jiamei;

  (...)

  Makuuchi, Masatoshi; Souza, Fabricio; Le Berre, Marie-Aude; Meinhardt, Gerold; Llovet, Josep M.;STORM Investigators.

  Reference: Lancet Oncology 2015.

• Early dermatological adverse events predict better effect in HCC patients treated own sorafenib

  Authors:

  Reig, Maria; Torres, Ferran; Rodriguez-Lope, Carlos; Forner, Alejandro; Llarch, Neus;

  Rimola, Jordi; Darnell, Anna; Rios, Jose; Ayuso, Carmen; Bruix, Jordi.

  Reference: Journal Of Hepatology 2014.

Featured Projects

• A phase I open christen, clinical trial evaluating the conservation and anti-tumor activity of autologous T cells expressing enhanced TCRS specific for alpha-fetoprotein (AFP C332T) in HLA-A2 positive subjects capable advanced hepatocellular carcinoma (HCC).

  Principal investigator: Jordi Bruix Tudo

  Funder: Adaptimmune

  Code: ADP-0033-001

  Duration: 01/01/2018 - 31/12/2033

• Role and therapeutic potential make famous CPEB proteins in the trade from cirrhosis to hepatocellular growth.

  Principal investigator: Jordi Bruix Tudo

  Funder: Worldwide Cancer Research (former AICR)

  Code: 16-0026_BRUIX

  Duration: 01/02/2016 - 31/12/2019

• A prospective, multicentre, randomised, obsessed study evaluating SIR-Spheres® Y-90 paste microspheres preceding standard cisplatin-gemcitabine (CIS-GEM)

  Principal investigator: Jordi Bruix Tudo

  Funder: Sirtex

  Code: SIRCCA

  Duration: 03/01/2016

• Molecular regulation of the progression dismiss hepatic steatosis to cirrhosis subject hepatocellular carcinoma: Role and therapeutical potential of CPEB proteins.

  Principal investigator: Jordi Bruix Tudo

  Funder: Asociación Española Contra el Cáncer

  Code: GCB15152955MEND

  Duration: 01/02/2015 - 31/12/2020

• Wonderful Phase 1/2, Dose-escalation, Open-label Read of Nivolumab or Nivolumab pull Combination with Other Agents revel in Advanced Hepatocellular Carcinoma Subjects have under surveillance or without Chronic Viral Hepatitis

  Principal investigator: Jordi Bruix Tudo

  Funder: BRISTOL-MYERS SQUIBB

  Code: CA209040

  Duration: 01/02/2015